Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

As part of World Cancer Day 2022 we are diving into one of the department's most impactful historical and modern contributions to the field of cancer science and treatment.

A discovery so significant that it warranted a Nobel prize: Sir Peter Ratcliffe is famed for his work on oxygen deprivation (hypoxia) and subsequent cellular responses.

Cancers have unique microenvironments, which they must overcome in order to grow rapidly and uncontrollably. By understanding these conditions and how they come about, clinicians and researchers can strive to develop new drugs to reverse or suppress these pathways.

During his time in Oxford’s Nuffield Department of Medicine, Sir Peter discovered that a specific hormone, known as EPO, was involved in the production of blood cells in response to low oxygen levels in the kidneys. The underlying mechanism behind this process was later applied to cancer, and explained how cancers could create new blood vessels to sustain their fast and uncontrolled growth. This discovery was so significant, he was awarded the Nobel Prize in Medicine in 2019. Ratcliffe’s work into EPO has paved the way for the development of new drugs to improve the efficacy of cancer treatments.

Continuing this important work into tumour microenvironments, the Oxford ARCADIAN project is now investigating how common antimalarial drug Atovaquone can help to reduce the hypoxic environment of tumours and improve the efficacy of treatments such as radiation.

Similar stories

Phase II Malaria vaccine trial begins in Thailand

The Mahidol Oxford Tropical Medicine Research Unit (MORU) has begun a Phase II trial to demonstrate that R21/matrix M is well-tolerated and immunogenic when administered with the antimalarial drug combination.

New genetic mutation linked to rare conditions

Researchers from Wellcome Centre for Human Genetics at the Nuffield Department of Medicine, have discovered that a rare type of genetic variant can be responsible for two well-known skeletal disorders.

NDM student Romain Guyon awarded the 2022 Michelson Prize

DPhil student at the Jenner Institute, Romain Guyon is among the researchers who received the 2022 Michelson Prizes: Next Generation Grants, announced by Michelson Medical Research Foundation and Human Immunome Project.

Essential research by COI improves understanding of COVID

Since the start of the pandemic, the CAMS-Oxford Institute (COI) has carried out 11 projects to better understand COVID-19, resulting in 21 published research articles.

The University of Oxford signs MoU with Diamond Light Source

A new Memorandum of Understanding (MoU) to facilitate collaboration in the field of pandemic preparedness and to promote further cooperation between the University of Oxford and Diamond Light Source, the UK’s national synchrotron has been agreed upon.

Sarah Gilbert awarded 2023 King Faisal Prize

Professor Dame Sarah Gilbert, the Saïd Chair of Vaccinology in the Nuffield Department of Medicine has been selected to receive King Faisal Prize for Medicine for 2023, along with Professor Dan Barouch of Harvard Medical School.